BioNTech's Defining Quarter: A Founder's Exit, a Halved Revenue Base, and a Pipeline That Must Deliver

BioNTech's Q2 sales fell 59.4% to €105.6M, net loss widened, and 2026 guidance was cut as COVID vaccine demand wanes, but €16.6B liquidity funds oncology pipeline.

The numbers landing on BioNTech's desk last Tuesday were never going to be pretty. What made them genuinely uncomfortable was the timing. Just one day earlier, the Mainz-based biotech had confirmed that Ugur Sahin — the co-founder who steered the company through the pandemic boom — will hand the chief executive role to Guido Oelkers by February 1, 2027 at the latest. The result is a leadership transition unfolding against the sharpest revenue contraction in the company's post-COVID history.

Second-quarter sales fell 59.4 percent year-on-year to €105.6 million, down from €261 million in the same period of 2025. The company pointed to weakening global demand for its COVID-19 vaccine, with Germany in particular drawing down existing inventories rather than placing fresh orders. The timing of milestone payments from out-licensed research programs also shifted, adding to the drag. On a reported basis, the net loss widened to €820.8 million, while the adjusted figure came in at €562.3 million — or minus €2.22 per share.

Management responded by slashing full-year guidance. Revenue for 2026 is now expected between €1.6 billion and €1.9 billion, down from the €2.0 billion to €2.3 billion range previously communicated. At the same time, the company trimmed its cost outlook: adjusted research and development expenses are now projected at €2.0 billion to €2.3 billion, versus an earlier forecast of up to €2.5 billion — a clear attempt to offset the shrinking vaccine franchise while continuing to fund an ambitious oncology pipeline.

A Stock in Transition, Not Free Fall

The market's reaction has been notably measured. Shares closed Monday at €80.30, up 1.77 percent on the week, leaving the stock roughly 4.49 percent below its 200-day moving average. That gap is slightly wider than the 4.26 percent deficit recorded when the stock traded at €80.45 — but the equity remains about 17.70 percent above its 52-week low. Market capitalization stands at approximately €19.97 billion.

That constellation — a stock trading below its long-term trend yet well off its lows — describes a company in the middle of a repositioning rather than one in crisis. The question is whether the repositioning works before the cash cushion starts to erode.

The €16.6 Billion Question

BioNTech ended the quarter with €16.6 billion in liquidity, which funds a pipeline of more than 17 pivotal readouts expected through 2030 and beyond. Six registration-enabling studies have already launched this year: five for the bispecific antibody candidate pumitamig and one for elfetabart drozuntecan, an antibody-drug conjugate targeting B7-H3. Three additional late-stage readouts spanning immunomodulators, ADCs, and mRNA cancer immunotherapies remain slated for 2026.

Early clinical signals offer grounds for optimism. Pumitamig posted a confirmed response rate of 62.5 percent in an early-stage lung cancer trial, while the antibody candidate gotistobart demonstrated a 54 percent reduction in mortality versus docetaxel in an earlier analysis phase. If those figures hold up in the late-stage data due this year, BioNTech would gain an oncology pillar capable of permanently reducing its dependence on COVID revenue.

Near-term support could come from a €613 million payment expected from the Bristol Myers Squibb collaboration in the third quarter — a sum that would meaningfully boost second-half results. Evercore ISI reaffirmed its "Outperform" rating on August 5, though it trimmed its price target from $135 to $130, signaling that even after the guidance cut, substantial upside is seen from current levels. A share buyback program of up to $1 billion is also underway, with roughly 1.69 million ADS repurchased in the second quarter at an average price of $89.50.

The Bear Case Is a Timeline Problem

The risks are less about the science than the clock. The guidance cut demonstrates that the COVID business is contracting faster than planned, while adjusted R&D costs remain elevated. If demand deteriorates further without new approvals arriving in time, additional forecast reductions could follow. The leadership change adds its own layer of uncertainty: until Oelkers formally takes the helm, his strategic priorities — and whether he maintains the current pipeline focus — remain unknown.

There is also the question of how much the newly approved vaccine variant can move the needle. In late July, the European Commission granted marketing authorization to Pfizer and BioNTech for a COVID-19 formula adapted to the XFG variant for the 2026/2027 season, covering individuals aged six months and older. It is a positive development, but one that operates in a market of structurally declining vaccination rates — and BioNTech's own revised guidance suggests the company does not expect a near-term reversal.

Two Tests Ahead

The immediate catalysts are now clearly defined. The €613 million BMS payment, expected in the third quarter, serves as a short-term liquidity test. The three late-stage readouts scheduled for later this year represent the structural proof point: whether the oncology strategy can genuinely replace the COVID franchise before the cash pile begins to shrink meaningfully.

If both go well, the stock could stabilize within its current consolidation band between the 50-day moving average of €79.72 and the 200-day average. If the data disappoint or the payment slips, the gap to the long-term trend is more likely to widen than close. For investors, the coming months will determine whether this is a transitional year — or the beginning of a longer adjustment.